Literature DB >> 10886724

Isoproterenol-induced myocardial injury resulting in altered S100A4 and S100A11 protein expression in the rat.

S Inamoto1, S Murao, M Yokoyama, S Kitazawa, S Maeda.   

Abstract

S-100 proteins (S100) are characterized by calcium-binding ability with two structural EF hands. Several S100 are expressed in cardiomyocytes and thought to play a crucial role in calcium signaling. To examine whether the expression of S100 is a response to detectable myocardial damage or regeneration, we investigated, immunohistochemically, the expression of S100A4 and S100A11 in the isoproterenol (ISP)-treated rat heart. Definite expression of S100A4 and S100A11 was demonstrated in normal cardiomyocytes, and their staining patterns were enhanced in the ISP-treated rat heart, suggesting the possible involvement of S1-A4 and S100A11 in ISP-induced myocardial damage.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10886724     DOI： 10.1046/j.1440-1827.2000.01069.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN： 1320-5463            Impact factor:   2.534


  10 in total

1.  Impaired cardiac contractility response to hemodynamic stress in S100A1-deficient mice.

Authors:  Xiao-Jun Du; Timothy J Cole; Nora Tenis; Xiao-Ming Gao; Frank Köntgen; Bruce E Kemp; Jörg Heierhorst
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

2.  Tissue profiling MALDI mass spectrometry reveals prominent calcium-binding proteins in the proteome of regenerative MRL mouse wounds.

Authors:  Robert L Caldwell; Susan R Opalenik; Jeffrey M Davidson; Richard M Caprioli; Lillian B Nanney
Journal:  Wound Repair Regen       Date:  2008-02-13       Impact factor: 3.617

Review 3.  S100A1: a multifaceted therapeutic target in cardiovascular disease.

Authors:  David Rohde; Julia Ritterhoff; Mirko Voelkers; Hugo A Katus; Thomas G Parker; Patrick Most
Journal:  J Cardiovasc Transl Res       Date:  2010-07-20       Impact factor: 4.132

Review 4.  S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy.

Authors:  Carolin Kraus; David Rohde; Christian Weidenhammer; Gang Qiu; Sven T Pleger; Mirko Voelkers; Melanie Boerries; Andrew Remppis; Hugo A Katus; Patrick Most
Journal:  J Mol Cell Cardiol       Date:  2009-06-16       Impact factor: 5.000

Review 5.  Myocardial fibroblast-matrix interactions and potential therapeutic targets.

Authors:  Edie C Goldsmith; Amy D Bradshaw; Michael R Zile; Francis G Spinale
Journal:  J Mol Cell Cardiol       Date:  2014-01-26       Impact factor: 5.000

Review 6.  S100A4: a common mediator of epithelial-mesenchymal transition, fibrosis and regeneration in diseases?

Authors:  Mikael Schneider; Jakob L Hansen; Søren P Sheikh
Journal:  J Mol Med (Berl)       Date:  2008-03-06       Impact factor: 4.599

7.  Transcription analysis on response of porcine alveolar macrophages to Haemophilus parasuis.

Authors:  Yang Wang; Chong Liu; Ying Fang; Xiaoli Liu; Wentao Li; Shuqing Liu; Yingyu Liu; Yuxi Liu; Catherine Charreyre; Jean-Christophe Audonnet; Pin Chen; Qigai He
Journal:  BMC Genomics       Date:  2012-02-13       Impact factor: 3.969

8.  Characterisation of the developing heart in a pressure overloaded model utilising RNA sequencing to direct functional analysis.

Authors:  Matthew Parnall; Chrysostomos Perdios; Kar Lai Pang; Sophie Rochette; Siobhan Loughna
Journal:  J Anat       Date:  2019-11-14       Impact factor: 2.610

9.  S100 A and B expression in normal and inflamed human limbus.

Authors:  Mario Nubile; Manuela Lanzini; Roberta Calienno; Rodolfo Mastropasqua; Claudia Curcio; Alessandra Mastropasqua; Luca Agnifili; Leonardo Mastropasqua
Journal:  Mol Vis       Date:  2013-01-28       Impact factor: 2.367

10.  S100A4 as a Target of the E3-Ligase Asb2β and Its Effect on Engineered Heart Tissue.

Authors:  Simon Braumann; Tilo Thottakara; Sabrina Stücker; Silke Reischmann-Düsener; Elisabeth Krämer; Julia Groß; Marc N Hirt; Shirin Doroudgar; Lucie Carrier; Felix W Friedrich
Journal:  Front Physiol       Date:  2018-09-19       Impact factor: 4.566
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.